Endoscopic radiofrequency ablation under the control of ultrasonography as a new method of treatment of neuroendocrine pancreatic tumors and analgesia option for locally advanced forms of pancreatic cancer. First experience in Russia

Background. Radiofrequency ablation (RFA) of pancreatic NET up to 20 mm in size under endosonographic control (EUS) may become the method of choice in the treatment of this group of patients, as well as an option for analgesia in patients with locally advanced forms of pancreatic cancer.
Aim. Describe the RFA – EUS technique, evaluate the safety and efficacy of the RFA – EUS method in the treatment of NET of the pancreas, up to 2.0 cm in diameter, and ablation of the celiac plexus in a cohort of patients with locally advanced forms of pancreatic cancer in order to relieve pain.
Materials and Methods. In a prospective ongoing observational study conducted at the FSBI “N. N. Blokhin national Medical Research Center of Oncology” of the Ministry of Health of Russia from September 2022 to June 2023, data of 10 patients with resectable NET and unresectable malignant neoplasms of the pancreas were analyzed. The main method of treatment in 100 % of cases was RFA – EUS, performed for the first time in Russia. All patients at the first stage underwent esophagogastroduodenoscopy (EGDS) and endosonographic study with fine needle aspiration biopsy (EUS-TAB) to verify the diagnosis. At the second stage, all patients underwent RFA – EUS. The main evaluated parameter in the group of patients with NET was the absence of residual tumor tissue after RFA – EUS, according to Endo-US and MRI, the nature of changes in the pancreatic tissue after RFA was additionally assessed – fibrous or necrotic changes in the area of RFA – EUS. The main parameter evaluated in the group of patients with unresectable pancreatic cancer was the absence of pain within 8 weeks. and complete withdrawal from opioid analgesics 3–5 days after RFA – EUS.
Results. According to the results of a morphological study, the diagnosis of pancreatic NET was confirmed in 7 (70 %) patients, adenocarcinoma – in 3 (30 %). Technical success, defined as a complete endosonographic and radiological response 3 months after the intervention in the group of patients with pancreatic NET (n = 7; 70 %) and complete withdrawal of opioid analgesics at 3–5 days, with the preservation of the analgesic effect for 8 weeks. after RFA – EUS, was achieved in 100 % of cases (n = 3; 30 %). Return to opioid analgesics after 3 months RFA – EUS in the group of patients with adenocarcinoma of the pancreas (n = 3; 30 %) was noted in 20 % of cases (n = 2), which required re-intervention, in 10 % (n = 1) – it was not possible to estimate the duration of the analgesic effect due to the death of the patient 2 months after RFA – EUS, the median follow-up was 6 months.
Conclusion. The results of the study are the first experience of using RFA – EUS in the treatment of malignant neoplasms of the pancreas. EUS-guided RFA is an effective, minimally invasive and safe treatment for pancreatic NET, up to 2.0 cm in diameter, as well as an analgesic option for advanced pancreatic cancer. To determine the indications, contraindications and effectiveness of RFA in the radical and symptomatic treatment of malignant neoplasms of the pancreas, it is necessary to conduct large prospective multicenter studies.

1. Fitzgerald T.L., Hickner Z.J., Schmitz M. et al. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 2008;37:134–8. DOI: 10.1097/MPA.0b013e318163a329

2. Jilesen A.P., van Eijck C.H., Busch O.R. et al. Postoperative Outcomes of Enucleation and Standard Resections in Patients with a Pancreatic Neuroendocrine Tumor. World J Surg 2016;40:715–28. DOI: 10.1007/s00268-015-3341-9

3. Mehrabi A., Fischer L., Hafezi M. et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 2014;43(5):675–86. DOI: 10.1097/MPA.0000000000000110

4. Lee D.W., Kim M.K., Kim H.C. Diagnosis of pancreatic neuroendo crine tumors. Clin Endosc 2017;50:537–45. DOI: 10.5946/ce.2017.131

5. Choi J.H., Seo D.W., Song T.J. et al. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy 2018;50(11):1099–104. DOI: 10.1055/a-0583-8387

6. Oleinikov K., Dancour A., Epshtein J. et al. Endoscopic ultrasound guided radiofrequency ablation: a new therapeutic approach for pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2019;104:2637–47. DOI: 10.1210/jc.2019-00282

7. Houmani Z.S., Noureddine M.S. EUS-guided celiac plexus radiofrequency ablation using a novel device. VideoGIE 2020;5(9):395-6. DOI: 10.1016/j.vgie.2020.04.022

8. Lakhtakia S., Seo D.W. Endoscopic ultrasonography-guided tumor ablation. Dig Endosc 2017;29(4):486–94. DOI: 10.1111/den.12833

9. Taewoong medical USA: URL: https://taewoongusa.com/products/viva-combo-rf-generator-system/

10. Goldberg S.N., Mallery S., Gazelle G.S. et al. EUS-guided radiofrequency ablation in the pancreas: results in a porcine model. Gastrointest Endosc 1999;50(3):392–401. DOI: 10.1053/ge.1999.v50.98847

11. Carrara S., Arcidiacono P.G., Albarello L. et al. Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study. Endoscopy 2008;40(4):321–6. DOI: 10.1055/s-2007-995595

12. Kim H.J., Seo D.W., Hassanuddin A. et al. EUS-guided radiofrequency ablation of the porcine pancreas. Gastrointest Endosc 2012;76(5):1039–43. DOI: 10.1016/j.gie.2012.07.015

13. Rossi S., Ravetta V., Rosa L. et al. Repeated radiofrequency ablation for management of patients with cirrhosis with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2011;53(1):136–47. DOI: 10.1002/hep.23965

14. Rossi S., Dore R., Cascina A. et al. Percutaneous computed tomography-guided radiofrequency thermal ablation of small unresectable lung tumours. Eur Respir J 2006; 27(3):556–63. DOI: 10.1183/09031936.06.00052905

15. Atwell T.D., Schmit G.D., Boorjian S.A. et al. Percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. AJR Am J Roentgenol 2013;200(2):461–6. DOI: 10.2214/AJR.12.8618

16. Mohan H., Nicholson P., Winter D.C. et al. Radiofrequency ablation for neuroendocrine liver metastases: a systematic review. J Vasc Interv Radiol 2015;26(7):935–42. DOI: 10.1016/j.jvir.2014.12.009

17. Elias D., Baton O., Sideris L. et al. Necrotizing pancreatitis after radiofrequency destruction of pancreatic tumours. Eur J Surg Oncol 2004;30(1):85–7. DOI: 10.1016/j.ejso.2003.10.013

18. Girelli R., Frigerio I., Salvia R. et al. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg 2010;97(2):22–5. DOI: 10.1002/bjs.6800

19. Khoury T., Sbeit W., Napoléon B. Endoscopic ultrasound guided radiofrequency ablation for pancreatic tumors: A critical review focusing on safety, efficacy and controversies. World J Gastroenterol 2023;29(1):157–70. DOI: 10.3748/wjg.v29.i1.157

20. Rossi S., Viera F.T., Ghittoni G. et al. Radiofrequency ablation of pancreatic neuroendocrine tumors: a pilot study of feasibility, efficacy, and safety. Pancreas 2014;43(6):938–45. DOI: 10.1097/MPA.0000000000000133

21. Armellini E., Crino` S.F., Ballare` M. et al. Endoscopic ultrasound-guided radiofrequency ablation of a pancreatic neuroendocrine tumor. Endoscopy 2015;47(S 01):E600–1. DOI: 10.1055/s-0034-1393677

22. Pai M., Habib N., Senturk H. et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015;7(4):52–9. DOI: 10.4240/wjgs.v7.i4.52

23. Lakhtakia S., Ramchandani M., Galasso D. et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc 2016;83(1):234–9. DOI: 10.1016/j.gie.2015.08.085

24. Barthet M., Giovannini M., Lesavre N. et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study [published online ahead of print 22 January 2019]. Endoscopy 2019;51(9):836–42. DOI: 10.1055/a-0824-7067

25. Bang J.Y., Sutton B., Hawes R.H., Varadarajulu S. EUS-guided celiac ganglion radiofrequency ablation versus celiac plexus neurolysis for palliation of pain in pancreatic cancer: a randomized controlled trial (with videos). Gastrointest Endosc 2019;89(1):58–66. DOI: 10.1016/j.gie.2018.08.005